DeniseAYardleyMD

Clinical Trials

• Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer Start of enrollment: 2002 Mar 01

  Completed

  Phase 3

• Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer Start of enrollment: 2001 Feb 01

  Completed

  Phase 2

• Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Start of enrollment: 2001 Nov 01

  Completed

  Phase 2

• Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Start of enrollment: 2001 Jul 01

  Completed

  Phase 2

• Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer Start of enrollment: 2003 Nov 01

  Completed

  Phase 2

• Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer Start of enrollment: 2004 Mar 01

  Completed

  Phase 2

• Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer Start of enrollment: 2005 May 01

  Completed

  Phase 2

• Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Start of enrollment: 2005 Sep 01

  Completed

  Phase 2

• Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer Start of enrollment: 2006 Jan 01

  Completed

  Phase 2

• Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01

  Completed

  Phase 2

• Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer Start of enrollment: 2006 Oct 01

  Completed

  Phase 2

• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer Start of enrollment: 2006 Nov 01

  Completed

  Phase 2

• Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer Start of enrollment: 2007 May 01

  Completed

  Not Applicable

• Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2008 Jun 13

  Completed

  Phase 2

• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Start of enrollment: 2008 Dec 01

  Completed

  Phase 3

• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer Start of enrollment: 2009 Feb 01

  Completed

  Phase 2

• Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer Start of enrollment: 2009 Mar 01

  Completed

  Phase 1, Phase 2

• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer Start of enrollment: 2009 Apr 01

  Completed

  Phase 2

• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer Start of enrollment: 2009 Jun 01

  Completed

  Phase 1, Phase 2

• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer Start of enrollment: 2010 Feb 01

  Completed

  Phase 2

• Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer Start of enrollment: 2009 Jul 01

  Completed

  Phase 2

• A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer Start of enrollment: 2009 Feb 01

  Completed

  Phase 2

• Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer Start of enrollment: 2009 Dec 01

  Completed

  Phase 1, Phase 2

• Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer Start of enrollment: 2010 Oct 01

  Terminated

  Phase 1, Phase 2

• Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Start of enrollment: 2011 Sep 23

  Completed

  Phase 2

• Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer Start of enrollment: 2012 Jun 01

  Completed

  Phase 2

• Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01

  Completed

• A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26

  Completed

  Phase 2

• Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Start of enrollment: 2013 Mar 01

  Completed

  Phase 2

• BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29

  Completed

  Phase 2

• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01

  Active, not recruiting

  Phase 2

• Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases Start of enrollment: 2014 May 01

  Terminated

  Phase 2

• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14

  Completed

  Phase 3

• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17

  Completed

  Phase 3

• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01

  Completed

  Phase 2

• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10

  Completed

  Phase 2

• Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer Start of enrollment: 2014 Apr 01

  Withdrawn

  Phase 2

• A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09

  Terminated

  Phase 2

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02

  Terminated

  Phase 2

• ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer Start of enrollment: 2021 Jan 11

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all